NCT02203695 - Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2015

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions

Adenocarcinoma of the Prostate

Interventions

DRUG

Enzalutamide

Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)

RADIATION

SRT

Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx

Trial Locations (9)

Sibley Memorial Hospital, Washington D.C.

Suburban Hospital, Bethesda

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Indiana University, Lafayette

University of Michigan Health System, Ann Arbor

Karmanos Cancer Center, Detroit

University of Chicago Medical Center, Chicago

University of Utah - Huntsman Cancer Center, Salt Lake City

Oregon Health Sciences University, Portland